Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.50 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | SIRT6 | Q8N6T7 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 2/20 | 0.47 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19221745 | 0.86 | MAPT (0.53) | MAPTHRH3MEN1KMT2ASIRT6 | |
| SCHEMBL19221744 | 0.86 | MAPT (0.53) | MAPTHRH3MEN1KMT2ASIRT6 | |
| SCHEMBL5206407 | 0.78 | MAPT (0.51) | MAPTHRH3MEN1KMT2AALDH1A1 | |
| SCHEMBL19221763 | 0.78 | MAPT (0.56) | MAPTMEN1KMT2ASIRT6ALDH1A1 | |
| SCHEMBL5206416 | 0.78 | MAPT (0.51) | MAPTHRH3MEN1KMT2AALDH1A1 | |
| SCHEMBL25175455 | 0.77 | MAPT (0.55) | MAPTHRH3MEN1KMT2ASIRT6 | |
| SCHEMBL29104 | 0.77 | MAPT (0.56) | MAPTHRH3MEN1KMT2ASIRT6 | |
| SCHEMBL25189631 | 0.77 | MEN1 (0.60) | MAPTHRH3MEN1KMT2ASIRT6 | |
| SCHEMBL28619 | 0.77 | HPGDS (0.52) | MAPTHRH3MEN1KMT2ASIRT6 | |
| SCHEMBL27832 | 0.77 | SIRT6 (0.59) | MAPTHRH3MEN1KMT2ASIRT6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040127717-A1 | Hydroxamic and carboxylic acid derivatives | MONTANA JOHN GARY (GB) | 2004-07-01 | — | — | US | disclosed |
| US-6680338-B2 | MATRIX METALLOPROTEINASE AND TUMOR NECROSIS FACTOR INHIBITORS; ANTICARCINOGENIC AGENTS; RHEUMATOID ARTHRITIS | DARWIN DISCOVERY LTD. (GB) | 2004-01-20 | — | — | US | disclosed |
| US-20030236416-A1 | HYDROXAMIC AND CARBOXYLIC ACID DERIVATIVES | DARWIN DISCOVERY LIMITED (GB) | 2003-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030236416-A1 | HYDROXAMIC AND CARBOXYLIC ACID DERIVATIVES | HCAR1, HCAR2, HCAR3 | MAPT 4860/4885HRH3 139/4885MEN1 3372/4885 |
| US-20040127717-A1 | Hydroxamic and carboxylic acid derivatives | HCAR1, HCAR2, CBR1 | MAPT 4865/4885HRH3 78/4885MEN1 3026/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.